glucose.jpgIPNews® – The Federal Circuit on Friday gave Abbott Diabetes Care Inc. another shot at proving that its two patents for a diabetes-related glucose monitoring system were not invalid in light of prior art, as the U.S. Patent and Trademark Office had found upon reexamination.

The PTO’s Board of Patent Appeals and Interferences adopted unreasonable claim constructions regarding two key terms in the patents, the appeals court ruled. The Federal Circuit vacated the board’s decisions as to the patentability of Abbott’s independent claims at issue and remanded the case for the board to apply the correct claim constructions. To continue reading, click: Federal Circuit Breathes New Life Into Abbott Glucose Monitor Patents